tradingkey.logo
tradingkey.logo
Search

Novocure Ltd

NVCR
Add to Watchlist
16.310USD
-0.720-4.23%
Close 07-28 16:00ETQuotes delayed by 15 min
1.89BMarket Cap
LossP/E TTM

TradingKey Stock Score of Novocure Ltd

Currency: USD Updated: 2026-07-27

Key Insights

Novocure Ltd's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 42 out of 199 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 28.83.In the medium term, the stock price is expected to trend up.Despite a good stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Novocure Ltd's Score

Industry at a Glance

Industry Ranking
42 / 199
Overall Ranking
116 / 4282
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Positive

Novocure Ltd Highlights

StrengthsRisks
NovoCure Limited is a global oncology company with a proprietary platform technology called Tumor Treating Fields (TTFields), which are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. The Company's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Its Optune Gio is approved by the FDA under the Premarket Approval pathway for the treatment of adult patients with newly diagnosed glioblastoma together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Its Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic non-small cell lung cancer concurrent with PD-1/PD-L1 inhibitors or docetaxel following progression on or after a platinum-based regimen.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 28.67% year-on-year.
Fairly Valued
The company’s latest PE is -11.10, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 99.30M shares, decreasing 10.29% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 873.45K shares of this stock.

Analyst Rating

Based on 7 analysts
Buy
Current Rating
28.833
Target Price
+63.36%
Upside Space

FAQs

How does TradingKey generate the Stock Score of Novocure Ltd?

The TradingKey Stock Score provides a comprehensive assessment of Novocure Ltd based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Novocure Ltd’s performance and outlook.

How do we generate the financial health score of Novocure Ltd?

To generate the financial health score of Novocure Ltd, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Novocure Ltd's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Novocure Ltd.

How do we generate the company valuation score of Novocure Ltd?

To generate the company valuation score of Novocure Ltd, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Novocure Ltd’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Novocure Ltd’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Novocure Ltd.

How do we generate the earnings forecast score of Novocure Ltd?

To calculate the earnings forecast score of Novocure Ltd, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Novocure Ltd’s future.

How do we generate the price momentum score of Novocure Ltd?

When generating the price momentum score for Novocure Ltd, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Novocure Ltd’s prices. A higher score indicates a more stable short-term price trend for Novocure Ltd.

How do we generate the institutional confidence score of Novocure Ltd?

To generate the institutional confidence score of Novocure Ltd, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Novocure Ltd’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Novocure Ltd.

How do we generate the risk management score of Novocure Ltd?

To assess the risk management score of Novocure Ltd, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Novocure Ltd’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Novocure Ltd.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.